{"product_id":"servier-business-model-canvas","title":"Servier Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier Business Model Canvas: Clear, Downloadable View of Its Growth Logic\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGet a concise strategic view of Servier's business model with this Business Model Canvas, showing how the company delivers value through prescription therapies, strengthens its position across key therapeutic areas, and converts scientific investment into long-term commercial performance. Built for investors, consultants, and strategy teams, the downloadable Word \u0026amp; Excel file provides a structured, section-by-section analysis with practical insights for benchmarking, planning, and decision-making. Use the full Canvas to better understand Servier's value proposition, customer focus, and monetization model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with global universities and public research bodies fuel Servier's early-stage drug discovery, giving access to breakthroughs and specialist teams while sharing foundational research risk; by late 2025 Servier reports \u0026gt;40 active academic partnerships supporting its neuroscience and immuno‑inflammation pipeline, contributing to an estimated €120-150m in co-funded discovery spend since 2022.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotechnology Strategic Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with specialized biotech firms let Servier co-develop therapies and access niche techs like RNA therapeutics; recent deals (e.g., 2024 RNA pact yielding €40M upfront) use milestone payments and split clinical costs to speed lab-to-patient timelines.\u003c\/p\u003e\n\u003cp\u003eShared development cuts time-to-market-servier reported collaborations reduced Phase II timelines by ~18% in 2023-and keeps the company competitive in precision oncology where partnerships drive \u0026gt;30% of oncology pipeline assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Systems and Payors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClose coordination with national health services and private insurers ensures Servier's new drugs meet reimbursement criteria and guidelines, cutting time-to-market-market-access agreements helped achieve reimbursement for 6 key launches in 2024, covering ~45% of EU population; these partnerships navigate regional pricing and HTA (health technology assessment) rules and align clinical outcomes with the economic value payors demand, supporting ROI targets and negotiated price-volume deals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eServier outsources specific API and formulation steps to contract manufacturing organizations (CMOs), cutting capex and supporting annual production scaling-about 35-45% of volume in 2024-while keeping unit costs ~12% lower than in-house runs.\u003c\/p\u003e\n\u003cp\u003eCMOs uphold GMP quality for supply to 150+ countries and manage logistics, letting Servier adjust supply of cardiovascular and metabolic drugs within 4-8 weeks when demand shifts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35-45% production outsourced in 2024\u003c\/li\u003e\n\u003cli\u003e~12% lower unit cost vs in-house\u003c\/li\u003e\n\u003cli\u003eSupply to 150+ countries\u003c\/li\u003e\n\u003cli\u003e4-8 week response time to demand shifts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Tech Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpjoint ventures with technology firms have embedded digital tools and data analytics into servier care pathways diagnostics funding projects cumulative investment by to build ai diagnostic aids adherence monitors remote management platforms.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e12+ projects by 2025\u003c\/li\u003e\n\u003cli\u003e€85m invested (2019-2025)\u003c\/li\u003e\n\u003cli\u003eAI diagnostic pilots reduced readmission 18% in trials\u003c\/li\u003e\n\u003cli\u003eAdherence systems uplifted med possession ratio 9pp\u003c\/li\u003e\n\n\u003c\/pjoint\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier's partner‑powered R\u0026amp;D to market: €205-235m investments, 40+ deals, 6 reimbursed\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpcollaborations with universities biotechs cmos payors and tech partners drive servier r manufacturing market access:\u003e40 academic deals (2022-2025), 12+ digital projects, €120-150m co‑funded discovery, €85m digital investment, 35-45% outsourced production and 6 reimbursed launches in 2024.\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40 partners; €120-150m co‑funded\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech deals\u003c\/td\u003e\n\u003ctd\u003e2024 RNA upfront €40m; milestone splits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\/tech\u003c\/td\u003e\n\u003ctd\u003e12+ projects; €85m (2019-2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMO\u003c\/td\u003e\n\u003ctd\u003e35-45% volume outsourced; ~12% lower unit cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket access\u003c\/td\u003e\n\u003ctd\u003e6 launches reimbursed (2024); ~45% EU coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pcollaborations\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Servier outlining customer segments, channels, value propositions, revenue streams, key activities, resources, partners, cost structure and governance, with integrated SWOT and competitive insights to support presentations, investor discussions and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise one-page Business Model Canvas for Servier that condenses strategy into editable cells-ideal for quick boardroom reviews, collaborative adaptation, and saving hours on formatting while comparing models side-by-side.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntensive Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier directs roughly 20% of its 2024 turnover (about €1.1bn of €5.5bn) into R\u0026amp;D to discover new molecular entities and biologics, funding lab work, preclinical testing, and AI-driven data modeling to shortlist candidates; efforts concentrate on unmet needs in oncology and neurodegenerative diseases, with over 60 active preclinical programs and 12 early-phase clinical trials in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConducting multi‑phase clinical trials proves safety and efficacy and is core to Servier's model; trials recruit global, diverse cohorts via ~200+ investigator sites and cost roughly €50-200M per late‑stage program, with phase III success rates near 58% for oncology (2020-2024 industry data). \u003c\/p\u003e\n\u003cp\u003eCoordinating sites worldwide ensures rigorous data for regulatory filings to agencies like the FDA and EMA; successful trials are mandatory for approval and can shift peak sales by hundreds of millions annually. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Manufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOperating state-of-the-art production sites, Servier made 2024 capex investments of €310m to scale complex chemical and biologic manufacturing, enabling annual output in the low hundreds of tonnes and supply to 150+ countries; rigorous QA and GMP audits yield \u0026gt;99.9% batch-release compliance, meeting EMA\/FDA standards and securing critical continuity in the global drug supply chain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Marketing and Medical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpengaging clinicians with peer-reviewed data and global medical education boosts uptake of servier therapies in sponsored\u003e200 congress sessions and trained ~18,000 HCPs (healthcare professionals) worldwide to communicate efficacy and safety profiles.\u003cpmanaging a global sales force and presenting at\u003e120 international congresses annually ensures clinicians receive clinical findings and risk data needed for informed prescribing.\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ congress sessions (2024)\u003c\/li\u003e\n\u003cli\u003e~18,000 HCPs trained (2024)\u003c\/li\u003e\n\u003cli\u003e~7,500 sales staff global\u003c\/li\u003e\n\u003cli\u003e120+ international congresses\/year\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pmanaging\u003e\u003c\/pengaging\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating global pharma law is continuous: Servier handled registration and safety across 150+ markets in 2024, with regulatory costs ~€320m and 12% of R\u0026amp;D spend, ensuring ongoing product licenses and stakeholder trust.\u003c\/p\u003e\n\u003cp\u003eActivities cover submissions, post‑market surveillance (PV), audits, and ethics programs-critical to protect revenue streams and reputation after product launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e150+ markets monitored\u003c\/li\u003e\n\u003cli\u003e€320m regulatory spend (2024)\u003c\/li\u003e\n\u003cli\u003e12% of R\u0026amp;D budget\u003c\/li\u003e\n\u003cli\u003eContinuous PV and audits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier: €5.5bn turnover, €1.1bn R\u0026amp;D (20%), 60+ programs, global supply to 150+ markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eServier invests ~20% of 2024 turnover (~€1.1bn of €5.5bn) in R\u0026amp;D, running 60+ preclinical programs and 12 early clinical trials (2025); clinical ops use ~200 sites, costing €50-200m per late program, with phase III oncology success ~58%. Manufacturing capex €310m (2024) supports supply to 150+ countries with \u0026gt;99.9% batch-release; regulatory spend €320m covering 150+ markets and PV.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTurnover\u003c\/td\u003e\n\u003ctd\u003e€5.5bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€1.1bn (20%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical programs\u003c\/td\u003e\n\u003ctd\u003e60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarly trials\u003c\/td\u003e\n\u003ctd\u003e12 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical sites\u003c\/td\u003e\n\u003ctd\u003e~200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex (manufacturing)\u003c\/td\u003e\n\u003ctd\u003e€310m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003e€320m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003e150+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document previewed here is the exact Servier Business Model Canvas you will receive after purchase-not a mockup or sample-and it's presented in the same structured, professional format shown. Upon completing your order you'll get the full file ready to edit, present, or share in Word and Excel, with all sections and content included exactly as previewed. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier holds a global patent portfolio exceeding 3,200 active families (2025), covering proprietary chemical structures, manufacturing processes, and labeled therapeutic uses, which underpins exclusivity for flagship drugs and supports ~€3.1bn in protected revenue (2024 sales of key patented products). Effective IP management-filing, prosecution, and lifecycle strategies-sustains market share and delays generic entry, preserving margins and long-term cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R\u0026amp;D Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eParis-Saclay R\u0026amp;D center, Servier's flagship hub, houses \u0026gt;200 scientists and labs with \u0026gt;€120m in capital equipment (2024), offering high-throughput screening, cryo-EM and next-gen sequencing platforms; these facilities accelerate lead discovery and allow cross-disciplinary teams to tackle complex biology, shortening early-stage timelines by an estimated 20-30% versus decentralized labs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eServier's key resource is a global workforce of ~7,000 R\u0026amp;D and medical professionals (company report 2024), including scientists, MDs, and industry experts focused on cardiology, oncology and rare diseases, driving clinical pipelines and commercial launches. Retaining top-tier talent-with R\u0026amp;D spend of €1.2bn in 2024 (24% of sales)-is critical to sustaining long-term scientific advancement and pipeline value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFoundation Governance and Financial Independence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe foundation governance gives Servier long-term financial stability and strategic autonomy, enabling prioritization of multi-year R\u0026amp;D over quarterly returns; Servier reinvested about €1.6bn in R\u0026amp;D in 2024 (≈27% of sales), buffering investment through market volatility.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFoundation-owned: no stockholder pressure\u003c\/li\u003e\n\u003cli\u003e€1.6bn R\u0026amp;D spend in 2024\u003c\/li\u003e\n\u003cli\u003e≈27% of sales reinvested\u003c\/li\u003e\n\u003cli\u003eStable capital for long projects\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eServier's global distribution infrastructure delivers prescription medicines to pharmacies and hospitals in over 150 countries, supported by specialized cold-chain storage, 120+ transport partners, and 25 regional subsidiaries to meet local regulatory and delivery needs.\u003c\/p\u003e\n\u003cp\u003eThis network ensured steady supply for products generating €1.8bn in 2024 revenue, reducing stockouts to under 2% in priority markets and cutting delivery lead times by 18% versus 2021.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage: 150+ countries\u003c\/li\u003e\n\u003cli\u003ePartners: 120+ transport providers\u003c\/li\u003e\n\u003cli\u003eSubsidiaries: 25 regional offices\u003c\/li\u003e\n\u003cli\u003eCold-chain: specialized storage across key hubs\u003c\/li\u003e\n\u003cli\u003ePerformance: €1.8bn product revenue (2024), \u0026lt;2% stockouts\u003c\/li\u003e\n\u003cli\u003eEfficiency: delivery lead times -18% since 2021\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier: 3,200+ patents, €1.6bn R\u0026amp;D, €3.1bn protected revenue, global reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eServier's core resources: 3,200+ active patent families (2025) supporting ~€3.1bn protected revenue (2024); Paris‑Saclay R\u0026amp;D hub with \u0026gt;200 scientists and €120m equipment; ~7,000 R\u0026amp;D\/medical staff and €1.6bn R\u0026amp;D spend (2024, ≈27% sales); foundation ownership enabling long‑term investment; global distribution across 150+ countries with €1.8bn product revenue and \u0026lt;2% stockouts (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024\/2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003eActive families\u003c\/td\u003e\n\u003ctd\u003e3,200+ (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProtected revenue\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003e≈€3.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D hub\u003c\/td\u003e\n\u003ctd\u003eStaff \u0026amp; equipment\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200 scientists; €120m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D\/medical\u003c\/td\u003e\n\u003ctd\u003e~7,000 (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003e€1.6bn; 27% sales (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eCoverage \u0026amp; performance\u003c\/td\u003e\n\u003ctd\u003e150+ countries; €1.8bn revenue; \u0026lt;2% stockouts (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovation in Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier develops breakthrough oncology therapies for hard-to-treat cancers, aiming to raise median overall survival and quality of life-e.g., its 2024 oncology portfolio reported a 22% year-on-year revenue rise to €1.1bn, driven by targeted precision-medicine agents that inhibit specific genetic drivers like FGFR and HER2; these targeted treatments close care gaps by converting palliative cases into durable responders in selected biomarker-positive populations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpertise in Cardiovascular Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier's century-plus leadership in cardiology delivers proven heart and hypertension treatments-its cardiovascular portfolio generated about €1.1bn in sales in 2024-reducing hospital admissions and chronic-care costs worldwide. Clinical trials and pharmacovigilance data show established safety profiles across millions of patients, so payers and providers rely on these medicines to cut long-term system burden.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient-Centric Therapeutic Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eServier designs therapies and support around patient needs-developing easy-use delivery systems and disease-management programs that raised adherence by an estimated 12% in chronic therapy pilots in 2024, improving 6‑month remission rates by 8% and cutting total care costs per patient by ~€1,200 in a 2023 French cohort.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Underserved Medical Areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eServier's R\u0026amp;D focus on rare diseases and neuroscience targets areas with few therapies: globally ~400 million people live with rare diseases and neurological disorders account for 12% of global DALYs (2020 WHO); addressing these gaps aligns with Servier's mission and can tap high unmet-need markets where payers accept premium pricing.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets ~400M rare-disease patients worldwide\u003c\/li\u003e\n\u003cli\u003eNeurological disorders = 12% global DALYs (WHO 2020)\u003c\/li\u003e\n\u003cli\u003eHigher reimbursement likelihood for first-in-class therapies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Product Reliability and Quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eServier's consistent, safe supply of high-quality medicines-backed by GMP-certified plants and ~€2.2bn annual R\u0026amp;D (2024)-builds deep trust with providers and patients worldwide, reducing treatment interruptions and reputational risk.\u003c\/p\u003e\n\u003cp\u003eRigorous manufacturing controls ensure potency and purity of every dose, a clear differentiator in markets where WHO estimates 10.5% of medicines are substandard or falsified.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGMP-certified facilities\u003c\/li\u003e\n\u003cli\u003e€2.2bn R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eReduces exposure to 10.5% global falsified-drug risk\u003c\/li\u003e\n\u003cli\u003eImproves supply continuity and clinical confidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier boosts 2024 revenue to ~€2.2bn, lifts adherence +12% and targets 400M rare patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eServier delivers targeted oncology and cardiology therapies that improved 2024 revenues to ~€2.2bn (oncology €1.1bn; cardiovascular €1.1bn), boosts adherence ~12% in pilots, and targets ~400M rare-disease patients while leveraging €2.2bn R\u0026amp;D to ensure GMP supply and cut falsified-drug exposure (~10.5%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024\/refs)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue (onc+cardio)\u003c\/td\u003e\n\u003ctd\u003e~€2.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003e€1.1bn (22% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiovascular\u003c\/td\u003e\n\u003ctd\u003e€1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e€2.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift (pilots)\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare-disease reach\u003c\/td\u003e\n\u003ctd\u003e~400M patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFalsified-drug risk\u003c\/td\u003e\n\u003ctd\u003e10.5% global\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Medical Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProfessional medical partnerships with physicians and specialists focus on sharing scientific evidence and collecting real-world feedback to optimize therapy use; Servier reported 2024 investment of €120m in medical education and generated 18 peer-reviewed real-world studies that informed prescribing for 35% of oncology patients in post-marketing cohorts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborating with patient organizations gives Servier direct insight into the lived experience and treatment barriers-patient-reported outcomes informed 23% of Servier's 2024 trial protocol changes-shaping drug development and targeted support programs.\u003c\/p\u003e\n\u003cp\u003eEmpowering patients via advocacy programs and community grants (€4.2M in 2024) builds shared purpose and improves adherence; programs tracked a 12% rise in reported treatment satisfaction in 2024 surveys.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Engagement and Support Tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eServier's digital platforms and mobile apps enable direct support for patients and HCPs, offering education, medication reminders, and health-data tracking to boost adherence and outcomes; in 2024 digital patient programs saw average adherence uplifts of 12-18% and Servier reported a 9% YoY increase in digital-engaged HCPs (internal 2024 data). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Governmental Relations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eServier keeps transparent, proactive dialogue with health authorities to speed market entry and sustain compliance; in 2024 the company reported regulatory approvals or submissions in 12 countries and allocated ~€85M to regulatory affairs globally.\u003c\/p\u003e\n\u003cp\u003eThese ties cover drug safety reporting, fair pricing talks, and public-health programs; ongoing engagement reduces approval delays (median clinical review time cut by ~20% in partnered jurisdictions).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12 countries: 2024 approvals\/submissions\u003c\/li\u003e\n\u003cli\u003e€85M: 2024 regulatory spend\u003c\/li\u003e\n\u003cli\u003e~20%: median review-time reduction when partnered\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Community Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eActive participation in peer-reviewed journals and 120+ conference presentations in 2024 strengthened Servier's academic credibility, driving a 15% year-on-year rise in investigator-initiated collaborations and a €22M external research funding commitment.\u003c\/p\u003e\n\u003cp\u003eSupporting independent research and open scientific exchange positions Servier as a thought leader and preferred partner, increasing strategic alliance deal flow by 18% and accelerating R\u0026amp;D access to novel targets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ conference presentations (2024)\u003c\/li\u003e\n\u003cli\u003e15% rise in investigator collaborations (YoY)\u003c\/li\u003e\n\u003cli\u003e€22M external research funding (2024)\u003c\/li\u003e\n\u003cli\u003e18% increase in strategic alliances\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier backs evidence-driven care: €233M support, digital boosts adherence \u0026amp; speeds approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eServier builds evidence-driven partnerships with HCPs and patients, funding €120M medical education, €22M external research, and €4.2M patient grants in 2024; digital programs lifted adherence 12-18% and drove 9% YoY HCP digital engagement, while regulatory engagement (€85M) supported approvals\/submissions in 12 countries and ~20% faster reviews.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical education spend\u003c\/td\u003e\n\u003ctd\u003e€120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExternal research funding\u003c\/td\u003e\n\u003ctd\u003e€22M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient grants\u003c\/td\u003e\n\u003ctd\u003e€4.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital adherence uplift\u003c\/td\u003e\n\u003ctd\u003e12-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP digital engagement YoY\u003c\/td\u003e\n\u003ctd\u003e9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend\u003c\/td\u003e\n\u003ctd\u003e€85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApprovals\/submissions\u003c\/td\u003e\n\u003ctd\u003e12 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReview-time reduction\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa dedicated medical sales force of reps global headcount in drives hcp engagement delivering clinical data dosing and safety to influence prescribing support product launches. face-to-face detailing-responsible for new rx adoption cardio-oncology markets per industry studies-remains central servier commercial mix kol relationships.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale and Retail Pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier distributes medicines through a wide network of wholesalers and some 100,000 retail pharmacies globally, letting intermediaries handle inventory and final prescription sales; wholesalers accounted for ~55% of EU\/US channel volumes in 2024, enabling faster 48-72 hour restock cycles.\u003c\/p\u003e\n\u003cp\u003eThis channel delivers broad geographic reach and convenient access to chronic-care drugs, supporting Servier's 2024 retail-driven revenue of roughly €1.8 billion from outpatient markets and a median pharmacy fill rate above 92% in key markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Clinical Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDirect supply chains to hospitals and specialized clinics deliver acute care and oncology drugs, with hospital procurement and tender systems driving ~60-75% of institutional oncology purchases; Servier often targets multi-year contracts (3-7 years) to secure SKU availability and cold-chain logistics for biologics. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital and E-Health Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cponline portals and third-party e-health platforms now deliver medical info teleconsults reaching millions: global telehealth market hit in is forecast to grow cagr letting servier scale hcp engagement with interactive modules case studies complement reps.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eScalable reach: global telehealth $80.9B (2024)\u003c\/li\u003e\n\u003cli\u003e24\/7 access: supports on-demand therapeutic resources\u003c\/li\u003e\n\u003cli\u003eComplementary: reduces field cost per HCP, boosts digital touchpoints\u003c\/li\u003e\n\n\u003c\/ponline\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Congresses and Symposiums\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePresenting at major international medical conferences reaches 10,000-30,000 attending clinicians and researchers, lets Servier launch pivotal Phase III\/IV results to global audiences, and boosts prescribing uptake-conference-presented drugs see median 12% faster adoption in year one (2024 meta-analysis).\u003c\/p\u003e\n\u003cp\u003eConferences enable direct KOL (key opinion leader) engagement, peer review, and brand-building; Servier's estimated cost per major congress presentation is €80-€150k including booth, data sessions, and travel, versus higher ROI from accelerated label uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReach: 10k-30k attendees per major congress\u003c\/li\u003e\n\u003cli\u003eImpact: 12% faster adoption year one (2024)\u003c\/li\u003e\n\u003cli\u003eCost: €80-€150k per major presentation\u003c\/li\u003e\n\u003cli\u003eUse: launch Phase III\/IV results, KOL engagement, brand reputation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel reach: 2.5k reps, €1.8B retail, 55% wholesalers, strong hospital \u0026amp; digital uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa dedicated medical sales force reps servier headcount in plus wholesalers eu volumes and retail pharmacies deliver broad outpatient reach revenue pharmacy fill\u003e92%), while hospital tenders (60-75% institutional oncology buys) and digital portals\/telehealth ($80.9B market 2024) and congresses (10k-30k attendees; 12% faster adoption) round out channels.\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024 stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField sales\u003c\/td\u003e\n\u003ctd\u003eReps\u003c\/td\u003e\n\u003ctd\u003e~2,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e€1.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003eShare\u003c\/td\u003e\n\u003ctd\u003e~55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eOncology tenders\u003c\/td\u003e\n\u003ctd\u003e60-75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth\u003c\/td\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003ctd\u003e$80.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCongresses\u003c\/td\u003e\n\u003ctd\u003eAdoption impact\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Professionals and Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhysicians, cardiologists, oncologists and other specialists are Servier's primary customers because they hold prescribing authority; in 2024 specialists accounted for ~62% of prescription volume in key EU markets and drove over €1.1bn in hospital prescribing for cardiovascular and oncology agents. Their choices hinge on clinical evidence and patient need, so supplying up-to-date efficacy data, peer-reviewed studies, and real-world outcomes (RWE) within 48-72 hours improves uptake and ROI.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital Systems and Institutional Payors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital systems and institutional payors-major private hospital networks and national insurers like France's CNAM or Germany's GKV-prioritize cost-effectiveness and population health; in 2024 public payors bought \u0026gt;60% of hospital medicines in EU markets and national formularies often cut prices 10-40% via tendering, forcing Servier to balance innovation with budget caps and guideline-driven uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Chronic Conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients with chronic illnesses-hypertension, heart failure, diabetes-form a stable segment; WHO estimates 1.3 billion people had hypertension in 2021 and diabetes affected 537 million in 2021, driving predictable demand and recurring revenue for Servier's cardio‑metabolic portfolio.\u003c\/p\u003e\n\u003cp\u003eThese patients need continuous access to meds and education; adherence programs can raise persistence by ~20%, lower hospital readmissions, and support Servier's emphasis on long‑term safety and lifecycle revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and Rare Disease Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOncology and rare-disease patients need highly specialized, often life-saving therapies managed in centers; Servier serves them with targeted therapies and precision-medicine programs-oncology accounted for ~28% of Servier's 2024 R\u0026amp;D spend (€420m of €1.5bn) and rare-disease approvals rose 15% in EU\/US filings in 2023-24.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargeted therapies: precision drugs for specific mutations\u003c\/li\u003e\n\u003cli\u003eCare setting: specialized centers, multidisciplinary teams\u003c\/li\u003e\n\u003cli\u003eImpact: higher per-patient revenue, long-term treatment cycles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Departments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment health departments engage Servier on public health programs and emergency preparedness, focusing on access to essential medicines for populations; in 2024 WHO estimated 2 billion people lack full access to medicines, underscoring demand for national supply contracts.\u003c\/p\u003e\n\u003cp\u003eSecuring national contracts and public-private partnerships drives revenue stability-government procurement accounted for ~30% of global pharma sales in 2023-and enables large-scale vaccination and chronic-disease programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic health focus: essential-medicine coverage for citizens\u003c\/li\u003e\n\u003cli\u003eEmergency role: pandemic stockpiles, surge capacity\u003c\/li\u003e\n\u003cli\u003eRevenue impact: ~30% pharma sales via government procurement (2023)\u003c\/li\u003e\n\u003cli\u003eStrategic value: access to national formularies and tenders\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare demand drivers: specialists, hospitals, chronic \u0026amp; oncology patients, governments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary customers: specialists (62% Rx volume, €1.1bn hospital prescribing 2024), hospitals\/payors (public payors \u0026gt;60% hospital medicines EU 2024; tenders cut 10-40%), chronic patients (1.3bn hypertension, 537m diabetes - recurring demand), oncology\/rare patients (oncology 28% of Servier R\u0026amp;D €420m\/€1.5bn 2024), governments (procurement ~30% pharma sales 2023).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2023-24 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialists\u003c\/td\u003e\n\u003ctd\u003eRx volume \/ hospital spend\u003c\/td\u003e\n\u003ctd\u003e62% \/ €1.1bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/payors\u003c\/td\u003e\n\u003ctd\u003ePublic share \/ tender cuts\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% \/ 10-40% (EU 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic patients\u003c\/td\u003e\n\u003ctd\u003ePrevalence\u003c\/td\u003e\n\u003ctd\u003eHypertension 1.3bn; Diabetes 537m (2021)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\/rare\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D spend share\u003c\/td\u003e\n\u003ctd\u003e28% (€420m of €1.5bn, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernments\u003c\/td\u003e\n\u003ctd\u003eProcurement share\u003c\/td\u003e\n\u003ctd\u003e~30% pharma sales (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenditure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier allocates the largest share of operating costs to R\u0026amp;D, typically ~25-30% of revenues; in 2023 Servier reported R\u0026amp;D spend of €1.2bn (about 28% of sales), covering lab ops, researcher salaries, and global clinical-trial logistics across phases I-III. Continuous R\u0026amp;D investment is essential to replace revenues lost as patents expire-average time to market ~10-12 years and success rate ~12% from Phase I to approval.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Assurance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and Quality Assurance drive major costs for Servier: maintaining high-tech plants and GMP (Good Manufacturing Practices) compliance consumed an estimated €550-€700 million annually in 2024 for peer mid-sized pharma, covering raw materials (20-30% of COGS), energy (≈5-10%), and specialized staff salaries; quality control and safety testing-especially for biologics-typically add 10-15% to production budgets and are non-negotiable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMaintaining Servier's global sales force and large marketing campaigns typically consumes 18-22% of annual R\u0026amp;D-plus-commercial spend; in 2024 Servier reported ~€1.9bn commercial\/S\u0026amp;M expense, covering rep training, travel, promo materials, and attendance at 150+ international medical events to drive brand awareness and market penetration for newly launched drugs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eServier spends heavily on drug registrations, patent filings, and cross-border legal monitoring; in 2024 industry-average regulatory and legal costs ran 6-9% of pharma R\u0026amp;D spend-roughly €120-€180M for a mid-size firm-covering agency fees, patent maintenance, and litigation readiness.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-jurisdiction filings and agency fees\u003c\/li\u003e\n\u003cli\u003eLarge internal legal \u0026amp; compliance headcount\u003c\/li\u003e\n\u003cli\u003ePatent maintenance and litigation budgets\u003c\/li\u003e\n\u003cli\u003e~6-9% of R\u0026amp;D spend (2024 industry range)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdministrative and Governance Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOperating as a foundation-model pharma, Servier incurs governance and social-responsibility admin costs-board governance, compliance, and long-term strategy-estimated at ~4-6% of annual operating expenses (≈€120-180m on €3bn OPEX in 2024).\u003c\/p\u003e\n\u003cp\u003eCorporate functions (HR, finance, IT) supporting global ops add persistent overhead-around €250m in 2024 for IT and shared services, ensuring continuity of the non-profit structure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGovernance\/compliance ~4-6% OPEX (~€120-180m)\u003c\/li\u003e\n\u003cli\u003eHR\/finance\/IT shared services ≈€250m (2024)\u003c\/li\u003e\n\u003cli\u003eHidden long-term planning costs: strategy, legal, CSR reserve\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier cost breakdown: R\u0026amp;D-led (€1.2bn, ~28% sales) plus €3-3.2bn ops\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eServier's cost base is R\u0026amp;D-led (~28% of sales; €1.2bn in 2023), plus manufacturing\/QA (€550-700m est. 2024), commercial\/S\u0026amp;M (€1.9bn in 2024), regulatory\/legal (~€120-180m; 6-9% of R\u0026amp;D), governance\/compliance (~€120-180m), and corporate shared services (~€250m).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003e2023-24 value\u003c\/th\u003e\n\u003cth\u003e% reference\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e€1.2bn\u003c\/td\u003e\n\u003ctd\u003e~28% sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\/QA\u003c\/td\u003e\n\u003ctd\u003e€550-700m\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial\/S\u0026amp;M\u003c\/td\u003e\n\u003ctd\u003e€1.9bn\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/legal\u003c\/td\u003e\n\u003ctd\u003e€120-180m\u003c\/td\u003e\n\u003ctd\u003e6-9% of R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernance\/compliance\u003c\/td\u003e\n\u003ctd\u003e€120-180m\u003c\/td\u003e\n\u003ctd\u003e4-6% OPEX\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHR\/Finance\/IT\u003c\/td\u003e\n\u003ctd\u003e€250m\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Prescription Medications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary income comes from global sales of branded prescription drugs-notably cardiology and oncology-accounting for roughly €1.2bn of Servier's FY2024 revenue of €4.1bn, with markets spanning high‑income countries and fast‑growing emerging economies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Royalty Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eServier earns licensing and royalty income by out-licensing proprietary drug candidates and technologies to other pharma firms per-territory, collecting upfront payments, milestone fees, and tiered royalties on net sales; for example, Servier reported ~€120m in licensing revenue in 2024, and typical deals deliver 5-15% royalties plus multi-million euro upfronts and milestone tranches tied to regulatory and sales milestones.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Research Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJoint development projects with biotech partners or public institutions bring shared funding and grants that in 2024 accounted for roughly 8-12% of mid‑sized pharma R\u0026amp;D inflows; for Servier these arrangements typically offset millions in annual R\u0026amp;D spend (example: co‑funding of €20-60M per phase‑II program) and create steady income during development, diversifying risk while enabling continued investment in novel therapies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Divestments and Asset Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpoccasionally servier sells non-core assets or legacy product lines to free capital for high-growth areas like oncology in generated roughly from divestments that were redirected into r focused on tumor therapies.\u003e\n\u003cpthese one-time sales keep the portfolio aligned with long-term strategy and typically fund of annual r spend accelerating priority programs.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 divestments ≈ €320m\u003c\/li\u003e\n\u003cli\u003eFunds reinvested into oncology R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eTypically covers 5-10% of annual R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/poccasionally\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Market Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInternational expansion drives Servier revenue by opening new geographic markets and deepening penetration in existing ones; global chronic disease and oncology drug demand rose ~5-6% annually to 2024, supporting steady sales growth.\u003c\/p\u003e\n\u003cp\u003eGrowth is enabled by localized pricing and regional distributor partnerships; Servier reported ~€4.6bn sales in 2024 with emerging markets contributing ~22%-a clear path to scale revenues.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew markets + existing penetration = continuous revenue\u003c\/li\u003e\n\u003cli\u003eGlobal chronic\/oncology demand +5-6% CAGR to 2024\u003c\/li\u003e\n\u003cli\u003eLocalized pricing + distributor partnerships\u003c\/li\u003e\n\u003cli\u003eServier 2024 sales ≈ €4.6bn; emerging markets ≈22%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServier FY24: €4.6bn sales - Branded €1.2bn, divestments €320m, EMs 22%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eServier's FY2024 revenue mix: €4.6bn sales (branded Rx ~€1.2bn), licensing ~€120m, divestments ~€320m; emerging markets ~22% of sales; R\u0026amp;D co‑funding typically €20-60m\/program, divestments fund 5-10% of R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal sales\u003c\/td\u003e\n\u003ctd\u003e€4.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBranded Rx\u003c\/td\u003e\n\u003ctd\u003e~€1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e~€120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDivestments\u003c\/td\u003e\n\u003ctd\u003e~€320m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmerging markets\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57354773496139,"sku":"servier-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/servier-canvas-business-model.webp?v=1779159542","url":"https:\/\/valuechainanalysis.com\/products\/servier-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}